What are the effects of omega-3 supplementation on anthropometric measurements and thyroid function in patients with Hashimoto's disease? A randomized controlled clinical trial.

Clin Nutr ESPENJul 22, 2026 (epub)
Clinical ResearchEndocrinology

Niayesh Naghshi, Behnam Mahdavi, Fatemeh Bourbour et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of omega-3 supplementation on thyroid function and anthropometric measurements in 50 patients with Hashimoto's disease. The study found that omega-3 supplementation significantly increased serum T4 levels (p = 0.032) and reduced anti-TPO levels (p = 0.040) compared to placebo over 12 weeks.

Key findings

  • Omega-3 supplementation significantly increased serum T4 levels (p = 0.032).
  • Anti-TPO levels were significantly reduced in the omega-3 group compared to placebo (p = 0.040).
  • No significant differences were observed in TSH and T3 levels between groups (p = 0.694 and p = 0.567).

Why it matters

Understanding the impact of omega-3 supplementation on thyroid function in Hashimoto's disease can inform treatment strategies aimed at improving thyroid hormone levels and reducing autoimmune activity, potentially enhancing patient outcomes.

Source

PubMed · PMID 42480759

Published in Clin Nutr ESPEN. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.